Back Login to subscribe 🔔 Set Alert

BBIO BridgeBio Pharma, Inc. Common Stock

15 min delay

Loading...

Loading...

Loading...

Loading...

Loading options…

CALLS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

PUTS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

Loading insider data…

Date	Headline	Sentiment
	Mizuho Maintains Outperform on BridgeBio Pharma, Raises Price Target to $110	92.85%
	Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President	66.5%
	BridgeBio Pharma Says To Expand State Medicaid Access To Marketed Medicine Via Generous Model; To Offer Attruby Via Medicare Part D Without Future Pricing Mandates; Agreement Does Not Impact ForgingBridges Copay Assistance Program; Does Not Expect Future Pricing Mandates; Terms Remain Confidential	62.01%
	Trump Administration Reaches New Drug Pricing Agreement With Nine Pharma Firms	54.01%
	Reported Earlier, BridgeBio Reports New Data Suggesting Attruby Could Help Reverse Some Heart Damage	59.97%
	BridgeBio Pharma Doses First Patient In ASCEND-ATTR Trial To Evaluate Effects Of Acoramidis To Enhance Cardiac Structure, Function, And Amyloid Burden In Individuals With Transthyretin Amyloid Cardiomyopathy	71.63%
	BridgeBio Pharma To Present Two Oral Presentations, Three Posters On New Acoramidis Data In Individuals With Transthyretin Amyloid Cardiomyopathy At European Society Of Cardiology Congress 2026	54.23%
	10 Health Care Stocks Whale Activity In Today’s Session	86.7%
	BridgeBio Pharma Announces Pricing Of 5,000,000-Share Secondary Offering By Selling Stockholder KKR Genetic Disorder; Company Receives No Proceeds	87.63%
	BridgeBio Pharma Launches Secondary Public Offering Of 5M Shares Of Common Stock By Selling Stockholder KKR Genetic Disorder L.P	95.44%

1
2
›